

# A phase II randomised feasibility study of chemoresection or surgical management in low risk non muscle invasive bladder cancer

<b>Submission date</b> 14/01/2015	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 15/01/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 18/08/2022	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-chemotherapy-and-surgery-for-early-bladder-cancer-caliber>

## Study website

<http://www.icr.ac.uk/our-research/our-research-centres/clinical-trials-and-statistics-unit/clinical-trials/caliber>

## Contact information

### Type(s)

Scientific

### Contact name

Mr Steven Penegar

### Contact details

Clinical Trials & Statistics Unit at the Institute of Cancer Research (ICR-CTSU)  
The Institute of Cancer Research  
London  
United Kingdom  
SM2 5NG

## Additional identifiers

### EudraCT/CTIS number

2013-005095-18

### IRAS number

**ClinicalTrials.gov number**

NCT02070120

**Secondary identifying numbers**

17640

## **Study information**

**Scientific Title**

A phase II randomised feasibility study of chemoresection or surgical management in low risk non muscle invasive bladder cancer

**Acronym**

CALIBER

**Study objectives**

Current hypothesis as of 10/04/2017:

To demonstrate that chemoresection has sufficient activity against NMIBC to warrant further investigation of its role as a potential alternative to surgical intervention for low risk NMIBC recurrence.

Previous hypothesis:

CALIBER aims to demonstrate that chemoresection will enable 60% of participants to avoid surgical intervention for low risk NMIBC recurrence, as assessed by response rate at 3 months.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

NRES Committee South Central - Hampshire B, 29/08/2014, ref: 14/SC/1223

**Study design**

Randomised; Interventional

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

## **Health condition(s) or problem(s) studied**

Topic: Cancer; Subtopic: Bladder Cancer; Disease: Bladder (superficial)

## **Interventions**

Chemoresection group: 4 once weekly instillations of 40mg MMC as outpatients

Surgical management group: Surgery according to local practice

## **Intervention Type**

Drug

## **Phase**

Phase II

## **Drug/device/biological/vaccine name(s)**

Mitomycin C

## **Primary outcome measure**

Complete response to chemoresection 3 months post-treatment

## **Secondary outcome measures**

Added 12/10/2016:

In the chemoresection group:

1. Treatment compliance

In both groups:

2. Time to recurrence in patients disease free at 3 months

3. Transurethral resection and biopsy rates

4. Progression-free survival

5. Toxicity

6. Quality of life

7. Health service utilisation

## **Overall study start date**

01/11/2014

## **Completion date**

30/09/2019

# **Eligibility**

## **Key inclusion criteria**

Current inclusion criteria as of 29/03/2017:

1. Written informed consent

2. NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of  $\leq 6$  using EORTC risk tables).

3. Histologically confirmed TCC at original diagnosis

4. Aged 16 or over

5. Satisfactory pre-treatment haematology values haemoglobin > 100 g/L and serum creatinine < 1.5xULN
6. Negative pregnancy test for women of child-bearing potential

Previous inclusion criteria from 12/10/2016 to 29/03/2017:

1. Written informed consent
2. NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of  $\leq 5$  using EORTC risk tables).
3. Histologically confirmed TCC at original diagnosis
4. Aged 16 or over
5. Satisfactory pre-treatment haematology values haemoglobin > 100 g/L and serum creatinine < 1.5xULN
6. Negative pregnancy test for women of child-bearing potential

Original inclusion criteria:

1. Written informed consent
2. NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 NMIBC with a risk of recurrence score of  $\leq 5$  using EORTC risk tables)
3. Histologically confirmed TCC at original and any subsequent diagnoses
4. Aged 16 or over
5. Satisfactory pre-treatment haematology values Hb > 100 g/L and serum creatinine < 1.5xULN
6. Negative pregnancy test for women of child-bearing potential

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Both

### **Target number of participants**

Planned Sample Size: 174; UK Sample Size: 174

### **Total final enrolment**

82

### **Key exclusion criteria**

Current exclusion criteria as of 29/03/2017:

1. Any history of: grade 3/high grade or  $\geq T1$  transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
2. Any history of histologically confirmed non-TCC bladder cancer
3. Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
4. Any prior treatment of the trial entry recurrence (including biopsy)
5. Previous MMC chemotherapy other than a single instillation at diagnostic surgery
6. Known allergy to MMC
7. Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
8. Known or suspected reduced bladder capacity (<100ml)

9. Significant bleeding disorder
10. Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
11. Active or intractable urinary tract infection
12. Urethral stricture or anything impeding the insertion of a catheter
13. Large narrow neck diverticula
14. Significant urinary incontinence
15. Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
16. Unable or unwilling to comply with study procedures or follow up schedule

Previous exclusion criteria from 12/10/2016 to 29/03/2017:

1. Any history of: grade 3/high grade or T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
2. Any history of histologically confirmed non-TCC bladder cancer
3. Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
4. Previous MMC chemotherapy other than a single instillation at diagnostic surgery
5. Known allergy to MMC
6. Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
7. Known or suspected reduced bladder capacity (<100ml)
8. Significant bleeding disorder
9. Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active
10. Active or intractable urinary tract infection
11. Urethral stricture or anything impeding the insertion of a catheter
12. Large narrow neck diverticula
13. Significant urinary incontinence
14. Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
15. Unable or unwilling to comply with study procedures or follow up schedule

Original exclusion criteria:

1. Risk of recurrence score >5 at original or any subsequent diagnoses (including any history of: grade 3 or T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year)
2. Previous MMC chemotherapy other than a single instillation at diagnostic surgery
3. Known allergy to MMC
4. Carcinoma involving the prostatic urethra or upper urinary tract (participants should have received an ultrasound of the upper urinary tract within 2 years prior to randomisation)
5. Known or suspected reduced bladder capacity (<100ml)
6. Significant bleeding disorder
7. Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active
8. Any other malignancy in the past 2 years (except: non-melanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix, DCIS/LCIS of the breast or prostate cancer in patients who have a life expectancy of >5 years upon trial entry)
9. Active or intractable urinary tract infection

10. Urethral stricture or anything impeding the insertion of a catheter
11. Large narrow neck diverticula
12. Significant urinary incontinence
13. Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
14. Unable or unwilling to comply with study procedures or follow up schedule

**Date of first enrolment**

28/01/2015

**Date of final enrolment**

04/09/2017

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Medway Maritime Hospital**

Windmill Road  
Gillingham  
United Kingdom  
ME7 5NY

**Study participating centre**

**Royal Bournemouth Hospital**

Castle Lane East  
Bournemouth  
United Kingdom  
BH7 7DW

**Study participating centre**

**Cumberland Infirmary**

Newtown Road  
Carlisle  
United Kingdom  
CA2 7HY

**Study participating centre**

**West Cumberland Hospital**  
Homewood Rd  
Whitehaven  
United Kingdom  
CA28 8JG

**Study participating centre**  
**Wythenshawe Hospital**  
Southmoor Road  
Wythenshawe  
United Kingdom  
M23 9LT

**Study participating centre**  
**Withington Community Hospital**  
Nell Lane  
Manchester  
United Kingdom  
M20 2LR

**Study participating centre**  
**Royal Devon and Exeter Hospital**  
Barrack Road  
Exeter  
United Kingdom  
EX2 5DW

**Study participating centre**  
**Royal Surrey County Hospital**  
Egerton Road  
Guildford  
United Kingdom  
GU2 7XX

**Study participating centre**  
**Basingstoke & North Hampshire Hospital**  
Aldermaston Road  
Basingstoke  
United Kingdom  
RG24 9NA

**Study participating centre**  
**St James's University Hospital**  
Beckett Street  
Leeds  
United Kingdom  
LS9 7TF

**Study participating centre**  
**Croydon University Hospital**  
London Road  
Thornton Heath  
United Kingdom  
CR7 7YE

**Study participating centre**  
**Freeman Hospital**  
Freeman Road  
Newcastle upon Tyne  
United Kingdom  
NE7 7DN

**Study participating centre**  
**Royal Oldham Hospital**  
Rochdale Road  
Manchester  
United Kingdom  
OL1 2JH

**Study participating centre**  
**Basingstoke & North Hampshire Hospital**  
Aldermaston Road  
Basingstoke  
United Kingdom  
RG24 9NA

**Study participating centre**  
**Ipswich Hospital**  
Heath Road  
Ipswich



United Kingdom  
IP4 5PD

**Study participating centre**  
**Leicester General Hospital**  
Gwendolen Road  
Leicester  
United Kingdom  
LE5 4PW

**Study participating centre**  
**New Cross Hospital**  
Wednesfield Road  
Wolverhampton  
United Kingdom  
WV10 0QP

**Study participating centre**  
**Darent Valley Hospital**  
Darent Wood Road  
Dartford  
United Kingdom  
DA2 8DA

**Study participating centre**  
**Broomfield Hospital**  
Court Road  
Chelmsford  
United Kingdom  
CM1 7ET

**Study participating centre**  
**James Cook University Hospital**  
Marton Road  
Middlesbrough  
United Kingdom  
TS4 3BW

**Study participating centre**

**Hereford County Hospital**  
Union Walk  
Hereford  
United Kingdom  
HR1 2ER

**Study participating centre**  
**University College Hospital**  
250 Euston Road  
London  
United Kingdom  
NW1 2PG

**Study participating centre**  
**Pinderfields Hospital**  
Aberford Road  
Wakefield  
United Kingdom  
WF1 4DG

**Study participating centre**  
**Macclesfield District General Hospital**  
Victoria Road  
Macclesfield  
United Kingdom  
SK10 3BL

**Study participating centre**  
**Dorset County Hospital**  
Williams Avenue  
Dorchester  
United Kingdom  
DT1 2JY

**Study participating centre**  
**St Richard's Hospital**  
Spitalfield Lane  
Chichester  
United Kingdom  
PO19 6SE

**Study participating centre**  
**Worthing Hospital**  
Lyndhurst Road  
Worthing  
United Kingdom  
BN11 2DH

**Study participating centre**  
**Worcestershire Royal Hospital**  
Charles Hastings Way  
Worcester  
United Kingdom  
WR5 1DD

**Study participating centre**  
**Royal Hallamshire Hospital**  
Glossop Road  
Sheffield  
United Kingdom  
S10 2JF

**Study participating centre**  
**Royal Preston Hospital**  
Sharoe Green Lane North  
Preston  
United Kingdom  
PR2 9HT

**Study participating centre**  
**Cheltenham General Hospital**  
Sandford Road  
Cheltenham  
United Kingdom  
GL53 7AN

**Study participating centre**  
**Southampton General Hospital**  
Tremona Road  
Southampton

United Kingdom  
SO16 6YD

**Study participating centre**

**Derriford Hospital**

Derriford Road  
Plymouth  
United Kingdom  
PL6 8DH

**Study participating centre**

**Northwick Park Hospital**

Watford Road  
Harrow  
United Kingdom  
HA1 3UJ

**Study participating centre**

**Princess Alexandra Hospital**

Hamstel Road  
Harlow  
United Kingdom  
CM20 1QX

## **Sponsor information**

**Organisation**

The Institute of Cancer Research

**Sponsor details**

-

London  
England  
United Kingdom  
SW7 3RP

**Sponsor type**

University/education

**Website**

<http://www.icr.ac.uk/>

ROR

<https://ror.org/043jzw605>

## Funder(s)

### Funder type

Government

### Funder Name

National Institute for Health Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Publication and dissemination plan

The main trial results will be published in a peer-reviewed journal, on behalf of all collaborators. Publication of primary outcome is planned for 2018.

### Intention to publish date

31/12/2019

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from [caliber-icrctsu@icr.ac.uk](mailto:caliber-icrctsu@icr.ac.uk).

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Other publications</a>	recruitment aids	01/11/2016		Yes	No
<a href="#">Other publications</a>	recruitment aids	01/05/2017		Yes	No

<a href="#">Results article</a>	results	01/03/2018		Yes	No
<a href="#">Results article</a>	results	01/04/2018		Yes	No
<a href="#">Results article</a>	12-month results	01/03/2019		Yes	No
<a href="#">Results article</a>	results	01/06/2020		Yes	No
<a href="#">Protocol file</a>	version 6	20/06/2017	18/08/2022	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No